BOLT |
Bolt Biotherapeutics, Inc. |
Sep 3, 2024 |
2 |
$0 |
4 |
Sep 6, 2024 |
Director |
BOLT |
Bolt Biotherapeutics, Inc. |
Sep 3, 2024 |
0 |
$0 |
3 |
Sep 6, 2024 |
Director |
PYXS |
Pyxis Oncology, Inc. |
Mar 26, 2024 |
1 |
$0 |
4 |
Mar 28, 2024 |
Director |
PYXS |
Pyxis Oncology, Inc. |
Sep 22, 2023 |
1 |
$0 |
4 |
Sep 26, 2023 |
Director |
APGN |
Apexigen, Inc. |
Aug 23, 2023 |
3 |
$0 |
4 |
Aug 25, 2023 |
Director |
PYXS |
Pyxis Oncology, Inc. |
Aug 23, 2023 |
3 |
$0 |
4 |
Aug 25, 2023 |
Director |
PYXS |
Pyxis Oncology, Inc. |
Aug 23, 2023 |
0 |
$0 |
3 |
Aug 25, 2023 |
Director |
ATRA |
Atara Biotherapeutics, Inc. |
Mar 2, 2023 |
1 |
-$18.4K |
4 |
Mar 6, 2023 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Mar 1, 2023 |
2 |
$0 |
4 |
Mar 3, 2023 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Nov 16, 2022 |
2 |
-$19.5K |
4 |
Nov 18, 2022 |
EVP, Head of R&D |
APGN |
Apexigen, Inc. |
Sep 29, 2022 |
1 |
$0 |
4 |
Oct 3, 2022 |
Director |
ATRA |
Atara Biotherapeutics, Inc. |
Aug 16, 2022 |
1 |
-$20.8K |
4 |
Aug 18, 2022 |
EVP, Head of R&D |
APGN |
Apexigen, Inc. |
Jul 29, 2022 |
0 |
$0 |
3/A |
Aug 24, 2023 |
Director |
ATRA |
Atara Biotherapeutics, Inc. |
May 17, 2022 |
1 |
-$20.6K |
4 |
May 19, 2022 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Mar 1, 2022 |
3 |
-$21.9K |
4 |
Mar 3, 2022 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Feb 10, 2022 |
3 |
-$32.1K |
4 |
Feb 14, 2022 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Jan 3, 2022 |
3 |
-$32.2K |
4 |
Jan 5, 2022 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Dec 1, 2021 |
3 |
-$41.8K |
4 |
Dec 3, 2021 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Nov 16, 2021 |
1 |
-$37.6K |
4 |
Nov 18, 2021 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Nov 2, 2021 |
3 |
-$34.2K |
4 |
Nov 4, 2021 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
Aug 17, 2021 |
1 |
-$27K |
4 |
Aug 19, 2021 |
EVP, Head of R&D |
ATRA |
Atara Biotherapeutics, Inc. |
May 18, 2021 |
1 |
-$75.4K |
4 |
May 20, 2021 |
EVP, Head of R&D |